|
TransPharma Medical Named Winner of 2007 Red Herring 100 Europe Award
LOD, ISRAEL, March 21, 2007 - TransPharma Medical Ltd., a specialty
pharmaceutical company focused on the development and commercialization of drug
products utilizing a proprietary active transdermal drug delivery technology,
announced today that it has been selected as a recipient of Red Herring 100
Europe, an award given to the top 100 private technology companies based in the
EMEA (Europe, Middle East and Africa) region each year.
“It is an honor to have been recognized by Red Herring as one of the top 100
private technology companies in our region,” said Dr. Daphna Heffetz, Chief
Executive Officer of TransPharma Medical. “The Red Herring 100 Europe is an
endorsement of our breakthrough RF-MicroChannel technology for transdermal drug
delivery. The first two drug products based on our technology are a proprietary
transdermal hPTH (1-34) product to treat osteoporosis and a transdermal hGH
product to treat growth hormone deficiency, which we are developing in
collaboration with Teva Pharmaceutical Industries. Both these products are
currently in phase I clinical trials, and we are encouraged by promising initial
results.”
Red Herring’s lists of top private companies are an important part of Red
Herring’s tradition of identifying new and innovative technology companies and
entrepreneurs. Companies like Google, eBay and Skype were spotted in their early
days by Red Herring editors, and touted as leaders that would change the way we
live and work.
“This year’s impressive list of winners demonstrates Europe’s emergence as a
major player in the global technology sector,” said Red Herring Editor-in-Chief,
Joel Dreyfuss. “The exceptional accomplishments of European technology companies
and entrepreneurs are a testament to the rapid advancements being made in
building the European innovation ecosystem.”
Red Herring’s editorial staff rigorously evaluated more than 700 private
companies through a careful analysis of financial data and subjective criteria,
including quality of management, execution of strategy, and dedication to
research and development.
As one of the winners, Dr. Daphna Heffetz, TransPharma Medical’s CEO, will
present the company at Red Herring’s Venture Market Europe (VME) 2007 event,
scheduled for March 25-27, at the Intercontinental Carlton in Cannes, France.
About TransPharma Medical
Established in 2000, TransPharma Medical Ltd. is a specialty pharmaceutical
company focused on the development and commercialization of drug products
utilizing a proprietary active transdermal drug delivery technology. Providing
an easy-to-use, cost-effective, at-home solution, TransPharma’s ViaDerm drug
delivery system enables the delivery of a wide variety of product candidates,
including hydrophilic small molecules, peptides and proteins. TransPharma aims
to develop multiple drug products through strategic partnerships with leading
pharmaceutical companies and through independent product development. For more
information, visit the Company's website at www.transpharma-medical.com.
About Red Herring
Red Herring is a global media company which unites the world’s best high
technology innovators, venture investors and business decision makers in a
variety of forums: a leading innovation magazine, an online daily technology
news service, technology newsletters and major events for technology leaders
around the globe. Red Herring provides an insider’s access to the global
innovation economy, featuring unparalleled insights on the emerging technologies
driving the economy. More information about Red Herring is available on the
Internet at www.redherring.com.
Company Contact:
Naomi Rabbie
Marketing Manager
+972-8-915-2201 x251
naomir@transpharma.co.il
|
